Skip to main content

Table 2 Participation rate, stratified by age groups and screening history

From: Preventing cervical cancer using HPV self-sampling: direct mailing of test-kits increases screening participation more than timely opt-in procedures - a randomized controlled trial

  

Directly mailed group

    

Opt-in group

   

Control group

  

Self-sampling

Cytology

Totala

   

Self-sampling

Cytology

Totala

   

Cytology

 

N

n (%)

n (%)

n (%)

PD1

(95% CI)

RR1 (95% CI)

N

n (%)

n (%)

n (%)

PD2

(95% CI)

RR2 (95% CI)

N

n (%)

Age (years)

 30–39

1236

231 (18.7)

264 (21.4)

495 (40.0)

13.4 (9.8–17.1)

1.50 (1.34–1.69)

1215

81 (6.7)

316 (26.0)

397 (32.7)

6.1 (2.5–9.7)

1.23 (1.09–1.39)

1251

333 (26.6)

 40–49

1300

271 (20.9)

260 (20.0)

531 (40.8)

13.3 (9.8–16.9)

1.49 (1.33–1.66)

1353

126 (9.3)

326 (24.1)

452 (33.4)

5.9 (2.4–9.4)

1.21 (1.08–1.36)

1342

369 (27.5)

 50–64

729

133 (18.2)

83 (11.4)

216 (29.6)

11.5 (7.1–15.9)

1.63 (1.35–1.99)

696

63 (9.1)

97 (13.9)

160 (22.9)

4.9 (0.6–9.2)

1.27 (1.03–1.57)

669

121 (18.1)

 Total

3265

635 (19.4)

607 (18.6)

1242 (38.0)

12.8 (10.6–15.0)

1.51 (1.40–1.62)

3264

270 (8.3)

739 (22.6)

1009 (30.9)

5.7 (3.5–7.9)

1.23 (1.13–1.32)

3262

823 (25.2)

Screened in previous screening roundb

 Not screened

1298

203 (15.6)

97 (7.5)

300 (23.1)

14.9 (12.2–17.7)

2.83 (2.29–3.49)

1272

76 (5.9)

95 (7.5)

171 (13.4)

5.2 (2.9–7.7)

1.65 (1.30–2.08)

1249

102 (8.2)

 Screened

1967

432 (21.9)

510 (25.9)

942 (47.9)

12.1 (9.0–15.1)

1.34 (1.24–1.44)

1992

194 (9.7)

644 (32.3)

838 (42.1)

6.3 (3.2–9.3)

1.17 (1.09–1.27)

2013

721 (35.8)

Screening historyb

 Unscreened

604

81 (13.4)

39 (6.5)

120 (19.9)

12.6 (8.8–16.4)

2.75 (1.96–3.84)

595

16 (2.7)

36 (6.1)

52 (8.7)

1.5 (−1.6–4.6)

1.21 (0.82–1.79)

567

41 (7.2)

 Underscreened

802

135 (16.8)

78 (9.7)

213 (26.6)

12.3 (8.4–16.2)

1.86 (1.52–2.28)

842

71 (8.4)

97 (11.5)

168 (19.9)

5.7 (2.1–9.3)

1.4 (1.13–1.73)

842

120 (14.3)

 Regularly screened

1859

419 (22.5)

490 (26.4)

909 (48.9)

13.2 (10.0–16.3)

1.37 (1.27–1.48)

1827

183 (10.0)

606 (33.2)

789 (43.2)

7.5 (4.3–10.6)

1.21 (1.12–1.31)

1853

662 (35.7)

  1. Participation rate is calculated as having a self-sample or a cervical cytology sample within 180 days after the second reminder. N: Number of randomized women. n: Number of participants in the group
  2. %: Row percentages. aTotal number of returned self-samples and cervical cytology samples. bSee classification of screening history for definitions
  3. Abbreviations:
  4. PD1: Participation difference in the total participation in the directly mailed group compared to the total participation in the control group
  5. RR1: Total participation in the directly mailed group compared to the total participation in the control group
  6. PD2: Participation difference in the total participation in the opt-in group compared to the total participation in the control group
  7. RR2: Total participation in the opt-in group compared to the total participation in the control group
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us